INTRODUCTION
Clear cell renal carcinoma (CCRC) is the most common tumor of the kidney, affecting roughly 50 000 new patients each year in the United States, and leading to 10 000 deaths. 1 CCRC displays both hereditary and sporadic patterns of occurrence. In cases of hereditary disease, CCRC is one of several manifestations of von Hippel-Lindau (VHL) syndrome, a genetic predisposition that is characterized by mutations in the VHL gene. Strikingly, sporadic development of CRCC is also associated with alterations or silencing of VHL in a majority of cases, demonstrating the critical role of VHL in CCRC.
The most well-understood role of VHL is the regulation of the cellular response to hypoxia. 2 VHL is a component of a ubiquitinconjugating complex that targets the a subunit of hypoxia inducible factor (HIF) for degradation. Oxygen-dependent posttranslational modifications of the HIFa subunits allow for an association with VHL that leads to degradation. Under low oxygen conditions (hypoxia), the HIF transcription complexes are stabilized and activated, leading to the transcription of a diverse set of target genes that are broadly involved in the adaptation to low oxygen, contributing to metabolic changes, angiogenesis and survival. In CCRC, genetic inactivation of VHL leads to constitutive HIF expression, which is critical for the growth of renal tumors. 3 Clear cell tumors are highly vascularized because of HIFmediated expression of vascular endothelial growth factor, and yet depend on anaerobic metabolism owing to the HIF-dependent activation of nearly all of the components of the glycolytic pathway. 4 Defining the HIF targets that have roles in renal cancer may provide an opportunity to target critical pathways. The macrophage migration inhibitory factor (MIF) is a 115 amino acidsecreted cytokine that is involved in a number of pathologies including autoimmunity, obesity and cancer. 5 MIF derives its name from its early identification as a factor that inhibited the random migration of macrophages. 6 Subsequently, however, MIF was found to promote inflammation by counteracting the function of glucocorticoids. 7 Indeed, MIF can activate lymphocytes, granulocytes and monocytes in a manner that prolongs immune responses. Significantly, MIF is also involved in cell-autonomous signaling in immune and non-immune cells both through autocrine signaling and intracellular functions. [8] [9] [10] [11] MIF is regulated by hypoxia and is a direct transcriptional target of HIF. [12] [13] [14] [15] Accordingly, MIF is overexpressed in a number of cancers, including gastric cancer, hepatocellular cancer, prostate cancer, colon cancer, glioblastoma, melanoma and adenocarcinoma of the lung. 12, [16] [17] [18] [19] [20] [21] Furthermore, MIF expression has a prognostic value for gastric, hepatocellular, prostate and colon cancers, in which MIF correlates with poorer prognosis. secreted, MIF can bind to several extracellular receptors to initiate signal transduction. The primary MIF receptors are CD74 and CD44, through which MIF can signal to extracellular signalregulated kinases (ERK)1 and 2 in the mitogen-activated protein kinase pathway, to Akt through phosphoinositide-3-kinase, and to Src. 10, 24, 25 CD74 can also form complexes with the chemokine receptors CXCR2 and CXCR4 to transmit MIF signaling to integrins in inflammatory cells. 26 Because MIF expression is activated by HIF, and CCRC is characterized by high levels of HIF, we sought to determine whether MIF has a role in the development of CCRC. Staining of tissue microarrays demonstrated that a very high proportion of CCRC tumor specimens are positive for MIF. High levels of tumorassociated MIF in CCRC also correlate with high levels of MIF in the circulation of CCRC patients. Inhibition of expression of MIF or the receptor proteins CD74 or CD44 demonstrated that the MIF signaling pathway is critical for growth and survival of CCRC cells in a cell-autonomous manner through the regulation of growth factor signaling and the cell cycle regulatory protein p27.
Together, these data demonstrate the critical role of MIF in CCRC and suggest that measuring MIF in patient blood plasma may provide a valuable diagnostic tool.
RESULTS AND DISCUSSION
MIF is highly expressed in CCRC tissues and elevated in patient blood plasma samples To assess the expression levels of MIF in CCRC tumor samples, we stained tumor microarrays comprising 128 primary tumor samples with a MIF-specific antibody. The 128 samples were scored by a pathologist as negative, moderate or high staining. Examples of the three types of staining are shown in Figure 1a . The pathological diagnoses of all samples were confirmed and the results were quantified. The vast majority of samples demonstrated positive staining (126/128, 98.4%). As shown in Figure 1b , 75.0% of the samples (96/128) demonstrated high staining, 23.4% demonstrated moderate staining (30/128) and only 1.6% were negative (2/128). MIF staining displayed a prominent membrane localization (Figure 1a ), consistent with a role for MIF as a secreted factor that signals through a receptor-mediated mechanism. In tumors expressing high levels of MIF, cytoplasmic and nuclear staining are also evident, suggesting potential intracellular roles for MIF as well. Together, these results demonstrate MIF is highly expressed in the vast majority of CCRC tumors.
In order to determine the mechanism of regulation of MIF in CCRC, we assessed the dependence of MIF transcriptional Tissue arrays were from two sources. One from the University of Pennsylvania has been described. 36 To create our own arrays, hematoxylin and eosin-stained slides of 36 clear cell renal cell carcinomas were reviewed to confirm the diagnoses. Tumor regions were marked and cores of 2 mm in diameter were placed into a tissue microarray recipient block using a manual arrayer (Beecher Instruments, Sun Prairie, WI, USA). Four mm thick sections were sectioned and placed onto superfrost slides. Tissues were stained with anti-MIF antibody (sc À 20121, Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 1:100 dilution with no antigen retrieval and biotin/avidin amplification following standard procedures. expression on VHL status in vitro. The expression levels of MIF and two classic HIF target genes were determined by quantitative realtime PCR in RCC4 cells and were compared with RCC4 cells that have reconstituted VHL expression. As shown in Figure 1c , vascular endothelial growth factor A, glucose transporter 1 and MIF all demonstrated significant decreases in expression upon reconstitution of VHL, suggesting that as we have noted in other systems 15 MIF expression in CCRC is regulated by the VHL/HIF pathway and overexpressed because of the loss of VHL.
Because of the observation that MIF is highly expressed in a large proportion of CCRC primary tumors, and is normally a secreted factor, we next assessed whether CCRC patients display increased levels of circulating MIF compared with individuals without CCRC. The plasma from 42 CCRC patients and 10 normal controls were collected using standard procedures and assessed by sandwich enzyme-linked immunosorbent assay for MIF expression. Dramatically, we observed that the mean level of plasma MIF in the 42 patient samples was sixfold greater than in healthy volunteers (0.634 ng/ml versus 0.106 ng/ml; P ¼ 0.00001, Mann-Whitney U test), suggesting MIF plasma levels may be useful as a blood-borne marker of CCRC (Figure 1d ).
MIF regulates proliferation and survival in CCRC cells. To assess the functional significance of MIF in CCRC cells, MIF expression was inhibited by lentiviral-mediated small hairpin (shRNA) in three established CCRC cell lines: RCC4, RCC10 and 786-O. All of these cell lines are characterized by the loss of VHL function and constitutive HIF activity. 27, 28 Quantitative real-time PCR and western blots were used to verify knockdown of MIF expression by two shRNAs. As shown in Figures 2a and 3a , all cells displayed significant decreases in MIF expression compared with shGFP (shRNA to green fluorescent protein) control cells. We assessed the growth characteristics of CCRC cells that lack MIF expression by proliferation assays. MIF knockdown reduced proliferation of all three cell lines (Figure 2b) . To inhibit MIF function by an alternative approach, we used the MIF small molecule antagonist ISO-1. 29 With increasing concentrations of ISO-1, we observed a dose-dependent inhibition of proliferation. Thus, by both shRNA and chemical antagonist, MIF inhibition decreases proliferation of CCRC cells.
The growth characteristics of CCRC cells were also measured by clonogenic survival. MIF inhibition caused a significant decrease in clonogenicity of each of the cell lines tested (Figure 2c ). In RCC4, for example, MIF knockdown led to 475% reduction in the number of colonies as well as the sizes of the colonies (Figure 2c,  inset) . Although decreased colony size may reflect decreased proliferation, decreased overall colony numbers suggest MIF also has a role in survival. MIF inhibition has been linked previously to cell death in other systems, 30 ,31 and thus we assessed death following MIF knockdown in CCRC cells. By trypan blue staining, flow cytometry and by western blots for cleaved caspase 3, however, we found no increases in cell death following MIF knockdown (data not shown, and Supplementary Figure S1) . Indeed, MIF knockdown did not dramatically alter cell cycle profiles of RCC4 cells, although we did observe moderate decreases in S phase cells and increases in G1 cells. Together, these data suggest MIF promotes growth and clonogenic survival of CCRC cells.
MIF signals through Src to promote degradation of p27
To assess the biochemical role of MIF in CCRC, protein lysates from RCC4 cells expressing shGFP or shMIF were analyzed by western blots. Both shMIF constructs led to reductions of MIF in cell lysates and conditioned media (Figure 3a) . MIF depletion led to decreased phosphorylation of ERK and increased levels of p27 (Figure 3a) . Steady-state levels of phospho-Akt were unchanged (Supplementary Figure S2 ). Although MIF signaling is known to involve phosphorylation of ERK, 10, 24 regulation of p27 by MIF has not been mechanistically described, though inverse correlations between the two have been observed. 32, 33 To understand how MIF affects p27, we assessed p27 mRNA by quantitative real-time PCR; however p27 mRNA was not appreciably changed in the absence of MIF (Figure 3b) . At the protein level, p27 is regulated by the ubiquitin-proteosome pathway in response to growth factor signaling. To determine whether p27 is regulated at the level of protein stability by MIF signaling, RCC4 shGFP and shMIF cells were incubated with the proteosome inhibitor MG132 for 16 h, harvested and analyzed by western blots. In untreated cells, shMIF caused a significant increase in p27 (Figure 3c ). In the presence of MG132, the levels of p27 in control cells increased, whereas in shMIF cells no significant changes in p27 were observed. Thus, MIF-deficient cells appear to have a decreased p27 turnover rather than an increased p27 production.
MIF has been previously found to activate Src signaling. 10, 11, 34 Recent studies have demonstrated that Src can phosphorylate and destabilize p27. 35 To test whether MIF signaling in CCRC cells leads to Src phosphorylation and is involved in p27 regulation, we treated serum-starved RCC4 cells with recombinant MIF protein.
As seen in Figure 3d , increasing levels of recombinant MIF led to dose-dependent increases in phospho-ERK and phospho-Src Tyr416 , and a decrease in p27. Although the phosphorylation of Src and the degradation of p27 were rapid, they were also sustained, increasing through 6 h after treatment (Figure 3e) . To inhibit Src, we treated the cells with the Src kinase inhibitor Dasatinib, and found that p27 degradation following MIF treatment was blocked, demonstrating MIF signals to p27 through Src in RCC4 cells. Together the data suggest that MIF signals via a Src-mediated pathway to degrade p27 and promote cell growth.
The CD74 and CD44 receptors promote proliferation and survival of CCRC cells As an extracellular signaling molecule, MIF signaling has been found to be mediated by the CD74 and CD44 receptors. 24, 25 To determine the roles of CD74 and CD44 in CCRC, we inhibited the expression of each receptor in RCC4 cells by shRNA, and assessed proliferation and clonogenic survival. Knockdown of CD74 and CD44, confirmed by quantitative real-time PCR and western blots (Figures 4a-d) led to significant decreases in both proliferation and colony survival (Figures  4b and c) . Similar to the levels of knockdown attained, shRNA inhibition of CD74 led to a decreased colony survival of 480% for the two shRNAs tested (Figure 4b ). Proliferation was likewise inhibited to a similar degree (Figure 4c ). For CD44, 70% knockdown of CD44 expression led to roughly a 70% decrease in colony survival for the two shRNAs, and an equivalent decrease in cell growth. To determine whether inhibition of CD74 or CD44 expression resulted in a similar effect on downstream signaling as MIF inhibition, we assessed the changes to p27 levels. Following either CD74 or CD44 knockdown, we observed significant increases in p27 expression (Figure 4d) . Importantly, addition of recombinant MIF led to decreased p27 in both control and MIF knockdown cells, but not CD74 or CD44 knockdown cells (Figure 4e ), confirming the signaling route.
MIF signaling promotes tumorigenicity in CCRC Finally we assessed the effect of MIF or CD74 knockdown on the tumorigenic potential of CCRC cells. 786-O shGFP, shMIF-1 or shCD74-1 cells were injected subcutaneously into nude mice, and followed over 6 weeks for tumor growth. Whereas control cells formed robust tumors by 6 weeks, both MIF and CD74 knockdown cells demonstrated significant decreases in tumor growth rate (Figure 4f ), suggesting the MIF signaling pathway has a major role in tumorigenic potential in CCRC. Together, the data presented in this report identify a novel autocrine mechanism of growth regulation in CCRC. We find that the vast majority of CCRC tumors stain highly positively for MIF expression owing to the loss of VHL. We further demonstrate that patients with CCRC tumors display enhanced circulating levels of MIF in their blood plasma. Functionally, inhibition of MIF expression causes a significant decrease in proliferation, clonogenicity and tumorigenic potential of CRCC cells. Mechanistically, we find that MIF signaling is manifested in increased phosphorylation of ERK and Src, and decreased levels of p27 because of Src signaling. Finally, MIF signaling depends on the CD74 and CD44 receptors, which also are critical for proliferation and survival of CCRC cells. In summary, we propose that high levels of MIF secreted by CCRC cells activate a positive signaling cascade through the engagement of the cell surface receptors CD74 and CD44. Importantly, we suggest that MIF can be a potential blood-borne biomarker of disease status or progression. 
